Martinez-Sanchez Carlos, Borrayo Gabriela, Carrillo Jorge, Juarez Ursulo, Quintanilla Juan, Jerjes-Sanchez Carlos
Executive Committee of RENASICA III, Mexico; Emergency Department and Coronary Critical Care, Instituto Nacional de Cardiología "Ignacio Chavez", Mexico.
Executive Committee of RENASICA III, Mexico; Hospital de Cardiologia, Centro Medico Nacional Siglo XXI, Mexico.
Arch Cardiol Mex. 2016 Jul-Sep;86(3):221-32. doi: 10.1016/j.acmx.2016.04.007. Epub 2016 May 30.
To describe current management and clinical outcomes in patients hospitalized with an acute coronary syndrome (ACS) in Mexico.
RENASICA III was a prospective multicenter registry of consecutive patients hospitalized with an ACS. Patients had objective evidence of ischemic heart disease; those with type II infarction or secondary ischemic were excluded. Study design conformed to current quality recommendations.
A total of 123 investigators at 29 tertiary and 44 community hospitals enrolled 8296 patients with an ACS (4038 with non-ST-elevation myocardial infarction/unstable angina [NSTEMI/UA], 4258 with ST-elevation myocardial infarction [STEMI]). The majority were younger (62±12years) and 76.0% were male. On admission 80.5% had ischemic chest pain lasting >20min and clinical stability. Left ventricular dysfunction was more frequent in NSTEMI/UA than in those with STEMI (30.0% vs. 10.7%, p<0.0001). In STEMI 37.6% received thrombolysis and 15.0% primary PCI. PCI was performed in 39.6% of NSTEMI/UA (early strategy in 10.8%, urgent strategy in 3.0%). Overall hospital death rate was 6.4% (8.7% in STEMI vs. 3.9% in NSTEMI/UA, p<0.001). The strongest independent predictors of hospital mortality were cardiogenic shock (odds ratio 22.4, 95% confidence interval 18.3-27.3) and ventricular fibrillation (odds ratio 12.5, 95% confidence interval 9.3-16.7).
The results from RENASICA III establish the urgent need to develop large-scale regional programs to improve adherence to guideline recommendations in ACS, including rates of pharmacological thrombolysis and increasing the ratio of PCI to thrombolysis.
描述墨西哥急性冠状动脉综合征(ACS)住院患者的当前管理及临床结局。
RENASICA III是一项对ACS住院连续患者进行的前瞻性多中心注册研究。患者有缺血性心脏病的客观证据;排除II型梗死或继发性缺血患者。研究设计符合当前质量建议。
29家三级医院和44家社区医院的123名研究者纳入了8296例ACS患者(4038例非ST段抬高型心肌梗死/不稳定型心绞痛[NSTEMI/UA],4258例ST段抬高型心肌梗死[STEMI])。大多数患者较年轻(62±12岁),76.0%为男性。入院时,80.5%有持续>20分钟的缺血性胸痛且临床稳定。NSTEMI/UA患者左心室功能障碍比STEMI患者更常见(30.0%对10.7%,p<0.0001)。在STEMI患者中,37.6%接受了溶栓治疗,15.0%接受了直接经皮冠状动脉介入治疗(PCI)。39.6%的NSTEMI/UA患者接受了PCI(早期策略占10.8%,紧急策略占3.0%)。总体医院死亡率为6.4%(STEMI患者为8.7%,NSTEMI/UA患者为3.9%,p<0.001)。医院死亡率最强的独立预测因素是心源性休克(比值比22.4,95%置信区间18.3 - 27.3)和心室颤动(比值比12.5,95%置信区间9.3 - 16.7)。
RENASICA III的结果表明迫切需要制定大规模区域项目,以提高对ACS指南建议的依从性,包括药物溶栓率以及提高PCI与溶栓的比例。